Technology | November 18, 2011

MedSolutions Announces Program to Reduce Unnecessary Implantable Cardiac Defibrillator Surgeries

November 18, 2011 – MedSolutions, a provider of medical cost management services, announced the launch of its implantable cardioverter defibrillator (ICD) surgery management program, which uses evidence-based guidelines to ensure the clinical appropriateness of ICD and CRT-D (cardiac resynchronization therapy defibrillator) implantation and directs members to the most qualified physicians and facilities.

With the cost of each ICD/CRT-D procedure averaging $34,000(1) and 157,082 procedures being performed annually(2), the ICD/CRT-D market represents approximately $5.3 billion in cost per year in the United States. In addition, the estimated annual growth rate of ICD/CRT-D procedures is 11 percent to 14 percent respectively.(3)

While clinical guidelines dictate waiting three months after diagnosis of heart failure and at least 40 days after a heart attack before ICD/CRT-D implantation, many physicians take a more aggressive approach to surgery. Earlier implantation has not been shown to benefit patients and, in some cases, the physicians or facilities providing the surgery may lack knowledge of evidence-based guidelines for ICD implants.(4)

Studies have shown that as many as 22.5 percent of ICD/CRT-D surgeries fail to meet established clinical guidelines, putting patients at greater risk for serious complications, including cardiac perforation, infection and even death. According to one recent study, patients who received an ICD despite failing to meet evidence-based guidelines had "significantly higher" risks of post-procedure complications and in-hospital death, as well as longer hospital stays, than individuals who met evidence-based criteria.(5)

"ICD surgery is an effective and beneficial treatment for tens of thousands of patients, but it can be extremely harmful when performed outside of accepted guidelines," said Gregg Allen, M.D., chief medical officer of MedSolutions. "Not only do unnecessary ICD surgeries put patients at risk for a number of life-threatening issues, they also represent avoidable health care costs of up to $36,000 per procedure(6), not including co-pays or additional costs to treat adverse outcomes."

MedSolutions' implantable cardioverter defibrillator surgery management program uses evidence-based clinical guidelines built upon the latest guidelines from the American College of Cardiology, American Heart Association, and Heart Rhythm Society and provides a dedicated cardiac queue, including cardiologists and nurses experienced with the complexities of cardiac care, to determine whether ICD implantations are clinically appropriate.

"By reducing unnecessary and inappropriate ICD/CRT-D surgeries and ensuring that patients who require surgery are directed to experienced physicians and quality facilities, our program helps improve health outcomes while limiting unnecessary costs associated with the procedure," Allen said. "As a result, members experience improved outcomes and payors can reduce total claims costs related to cardiac implantables by 10 percent to 15 percent."(7)

For more information: www.medsolutions.com


Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2023 — Findings from two new studies highlight the success of left bundle branch area pacing (LBBAP), or his ...

Home May 22, 2023
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2023 — Results from a pivotal clinical trial found a leadless pacemaker can deliver cardiac resynchronization ...

Home May 22, 2023
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure ...

Home October 27, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Subscribe Now